vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and JBG SMITH Properties (JBGS). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $127.6M, roughly 1.5× JBG SMITH Properties). Axsome Therapeutics, Inc. runs the higher net margin — -14.6% vs -35.7%, a 21.1% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -2.5%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -6.3%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
JBG SMITH PropertiesJBGSEarnings & Financial Report
JBG SMITH Properties is a publicly traded real estate investment trust based in Bethesda, Maryland.
AXSM vs JBGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $127.6M |
| Net Profit | $-28.6M | $-45.5M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | -47.5% |
| Net Margin | -14.6% | -35.7% |
| Revenue YoY | 65.0% | -2.5% |
| Net Profit YoY | 61.9% | 24.0% |
| EPS (diluted) | $-0.55 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $127.6M | ||
| Q3 25 | $171.0M | $123.9M | ||
| Q2 25 | $150.0M | $126.5M | ||
| Q1 25 | $121.5M | $120.7M | ||
| Q4 24 | $118.8M | $130.8M | ||
| Q3 24 | $104.8M | $136.0M | ||
| Q2 24 | $87.2M | $135.3M | ||
| Q1 24 | $75.0M | $145.2M |
| Q4 25 | $-28.6M | $-45.5M | ||
| Q3 25 | $-47.2M | $-28.6M | ||
| Q2 25 | $-48.0M | $-19.2M | ||
| Q1 25 | $-59.4M | $-45.7M | ||
| Q4 24 | $-74.9M | $-59.9M | ||
| Q3 24 | $-64.6M | $-27.0M | ||
| Q2 24 | $-79.3M | $-24.4M | ||
| Q1 24 | $-68.4M | $-32.3M |
| Q4 25 | -13.8% | -47.5% | ||
| Q3 25 | -27.0% | -27.5% | ||
| Q2 25 | -24.5% | -18.4% | ||
| Q1 25 | -46.9% | -44.7% | ||
| Q4 24 | -61.1% | -53.6% | ||
| Q3 24 | -59.8% | -22.4% | ||
| Q2 24 | -89.5% | -24.3% | ||
| Q1 24 | -89.7% | -30.1% |
| Q4 25 | -14.6% | -35.7% | ||
| Q3 25 | -27.6% | -23.1% | ||
| Q2 25 | -32.0% | -15.2% | ||
| Q1 25 | -48.9% | -37.9% | ||
| Q4 24 | -63.1% | -45.8% | ||
| Q3 24 | -61.7% | -19.8% | ||
| Q2 24 | -91.0% | -18.0% | ||
| Q1 24 | -91.1% | -22.2% |
| Q4 25 | $-0.55 | $-0.76 | ||
| Q3 25 | $-0.94 | $-0.48 | ||
| Q2 25 | $-0.97 | $-0.29 | ||
| Q1 25 | $-1.22 | $-0.56 | ||
| Q4 24 | $-1.54 | $-0.70 | ||
| Q3 24 | $-1.34 | $-0.32 | ||
| Q2 24 | $-1.67 | $-0.27 | ||
| Q1 24 | $-1.44 | $-0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $75.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.2B |
| Total Assets | $689.8M | $4.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $75.3M | ||
| Q3 25 | $325.3M | $64.4M | ||
| Q2 25 | $303.0M | $61.4M | ||
| Q1 25 | $300.9M | $81.3M | ||
| Q4 24 | $315.4M | $145.8M | ||
| Q3 24 | $327.3M | $137.0M | ||
| Q2 24 | $315.7M | $163.5M | ||
| Q1 24 | $331.4M | $220.5M |
| Q4 25 | $88.3M | $1.2B | ||
| Q3 25 | $73.7M | $1.2B | ||
| Q2 25 | $73.1M | $1.3B | ||
| Q1 25 | $53.2M | $1.6B | ||
| Q4 24 | $57.0M | $1.8B | ||
| Q3 24 | $92.9M | $1.9B | ||
| Q2 24 | $102.9M | $2.0B | ||
| Q1 24 | $144.0M | $2.1B |
| Q4 25 | $689.8M | $4.4B | ||
| Q3 25 | $669.3M | $4.4B | ||
| Q2 25 | $639.8M | $4.5B | ||
| Q1 25 | $596.7M | $4.7B | ||
| Q4 24 | $568.5M | $5.0B | ||
| Q3 24 | $561.5M | $5.2B | ||
| Q2 24 | $548.2M | $5.3B | ||
| Q1 24 | $545.7M | $5.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $73.3M |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $73.3M | ||
| Q3 25 | $1.0M | $8.9M | ||
| Q2 25 | $-32.4M | $18.8M | ||
| Q1 25 | $-43.4M | $12.9M | ||
| Q4 24 | $-26.2M | $129.4M | ||
| Q3 24 | $-18.6M | $26.4M | ||
| Q2 24 | $-30.1M | $23.8M | ||
| Q1 24 | $-53.5M | $37.0M |
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-53.6M | — |
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — | ||
| Q1 24 | -71.4% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
